Beam Therapeutics Inc

BEAM

$94.28

+232.8% (1 year change)

Market Cap

$6.26 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$29.43 - $138.52

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $6.26 Billion
Enterprise Value -
Dividend Yield $0.00 (0.0%)
1 Year Return +232.8%
52-Week High $138.52
52-Week Low $29.43
Beta 1.81
Outstanding Shares 66.4 Million
Avg 30 Day Volume 750 Thousand

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

Insider trades

No purchases

7,095 shares sold (1 transactions)

No purchases

25,338 shares sold (4 transactions)

No purchases

No sells

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

Similar stocks

Otonomy Inc
ORIC Pharmaceuticals Inc

News

Beam Therapeutics (BEAM) Shares Cross Above 200 DMA

Beam Therapeutics (BEAM) Shares Cross Above 200 DMA

In trading on Thursday, shares of Beam Therapeutics Inc (Symbol: BEAM) crossed above their 200 day moving average of $91.38, changing hands as high as $95.00 per share. Beam Therapeutics Inc shares...

iShook Finance iShook Finance, 4 days ago
Beam Therapeutics (NASDAQ:BEAM) Upgraded by Zacks Investment Research to Hold

Beam Therapeutics (NASDAQ:BEAM) Upgraded by Zacks Investment Research to Hold

Beam Therapeutics} stock has undergone multiple analysts rating changes in the recent past. Beam Therapeutics Upgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm iss...

Stock Market Daily Stock Market Daily, 6 days ago
Beam Therapeutics Stock Flashes Renewed Technical Strength

Beam Therapeutics Stock Flashes Renewed Technical Strength

Beam Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

Investor''s Business Daily Investor''s Business Daily, 6 days ago